Trial reportEuropean journal of endocrinology2015
A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice.
Trial report in European journal of endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 30 citations in OpenAlex.
- Association between microwave ablation and remission in patients with Graves' hyperthyroidism receiving continuous antithyroid drug treatment: a single-arm prospective study.Quantitative imaging in medicine and surgery · 2026Article
- High TRAb Titer at Diagnosis Predicts Persistent Positivity and Relapse in Graves' Disease after Prolonged Antithyroid Therapy.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- The evolving therapeutic landscape of Graves' disease in adults: present and future.European thyroid journal · 2025Review
- A short review of current knowledge regarding long-term treatment of Graves' disease with antithyroid drugs.Hormones (Athens, Greece) · 2025Review
- Long-term follow-up result of antithyroid drug treatment of Graves' hyperthyroidism in a large cohort.European thyroid journal · 2023Article
- Graves' Disease: Can It Be Cured?Endocrinology and metabolism (Seoul, Korea) · 2019Review
- Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence.International journal of endocrinology · 2017Review
- Recent Advances in Autoimmune Thyroid Diseases.Endocrinology and metabolism (Seoul, Korea) · 2016Review
- Hyperthyroidism.Lancet (London, England) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThere are scarce reports regarding the prognosis of a second course of antithyroid drug (ATD) therapy on recurrent Graves' disease (GD). The aim of this study was to assess the long-term remission rate after a second ATD therapy and verify significant clinical predictors of a remission.
designA prospective randomized clinical trial with long-term follow-up was conducted to evaluate the effects of a second course of ATD therapy.
methodsA total of 128 recurrent GD patients who had finished a first regular ATD therapy were enrolled in this study, and prescribed methimazole (MMI) treatment with titration regimen. The patients were randomly assigned to two groups when the drug doses were reduced to 2.5 mg daily (qd). Group 1 was discontinued with 2.5 mg qd after about 5 months. Group 2 was continuously reduced to 2.5 mg every other day (qod) after 5 months and then discontinued with 2.5 mg qod after about a further 5 months. The patients were followed for 48 months after drug withdrawal.
resultsOf the total number of patients, 97 cases (75.78%) achieved permanent remission at the end of follow-up, with the recurrence of 31 cases (24.22%). The remission rate of group 2 (84.62%) was significantly higher than that of group 1 (66.67%) (P=0.024). Cox regression showed that the hazard ratio for recurrence decreased under a high or high normal TSH level at drug withdrawal.
conclusionA second course of ATD therapy can bring about a satisfying long-term remission on recurrent GD. The drug dose of 2.5 mg qod and a high or high normal TSH level at drug withdrawal may increase the likelihood of permanent remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.